ClinicalTrials.gg
Not yet recruitingNCT06217042Updated Jan 22, 2024

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

A Phase 3 interventional study of HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate and gemcitabine; capecitabine in Pancreatic Cancer, sponsored by Fudan University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Fudan University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
524
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 88 studies testing oxaliplatin in Pancreatic Neoplasms — 13 open to participants now, 19 under way, 7 of them phase 3. Oxaliplatin · Pancreatic Neoplasms.

Planned enrollment
2nd of 83
524 · median 46
Started
2024
with 6 others
Phase 3
14 of 88
4 open now
Primary completion
2027-03
later than 10 of 18 live
Registered
82nd of 88
by date
Lead sponsor
2 of 88
Fudan University

Among the 88 studies testing oxaliplatin in Pancreatic Neoplasms, this one is the 2nd largest by planned enrollment of the 83 interventional ones that give a count, is one of 7 that started in 2024, is one of 14 in phase 3, reaches primary completion later than 10 of the 18 other live ones, and was the 82nd registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

13 of the 88 studies testing oxaliplatin in Pancreatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies testing oxaliplatin in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to look at the efficacy and safety of HR070803 in combination with 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to gemcitabine + capecitabine treatment as adjuvant therapy in patients with resected pancreatic cancer.

Read the detailed description

STUDY DESIGN/ Evaluation criteria Main criterion: efficacy. The main criterion is the disease-free survival. Disease-free survival is defined as the time from date of randomization until the date of the first cancer-related event, second cancer, or death from any cause. Patients without event at the time of analysis will be censored at the date of last follow-up visit.

Secondary criteria include Overall survival. OS is defined as the time from date of randomization until the date of death from any cause. Patients who are still living at the time of analysis will be censored at the date of last follow-up visit.

Secondary criteria also include 3-year disease-free survival rate/overall survival rate and 5-year disease-free survival rate/overall survival rate.

Tolerance Patients evaluable for toxicity must have received one investigational drug.

03

Conditions studied

  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. performance status 0 or 1
  2. confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1).
  3. of greater than or equal to 6 months.
  4. Full recovery from surgery and patient is scheduled to start treatment within 3 weeks to 12 weeks after surgery.
  5. Acceptable hematology parameters and blood chemistry levels.
  6. Able and willing to provide a written .

Exclusion criteria

Exclusion Criteria:

  1. Patients with pancreatic cancer originating from extrapancreatic ductal epithelium, including pancreatic neuroendocrine carcinoma, acinar cell carcinoma of the pancreas, pancreatoblastoma, and solid-pseudopapillary tumor;
  2. Presence of or history of or locally recurrent pancreatic adenocarcinoma.
  3. CA 19-9> 180 U / ml within 21 days of registration on study.
  4. Prior treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma.
  5. Severe infection (> grade 2), such as severe pneumonia, bacteremia, infection complications, etc. requiring inpatient treatment, occurred within four weeks before enrollment, and symptoms and signs of infection requiring intravenous antibiotic therapy (except for prophylactic antibiotics) occurred within two weeks before enrollment;
  6. Patients with cardiac clinical symptoms or diseases that are not well controlled, such as: (1) Patients with class 2 and above cardiac failure; (2) unstable angina; (3) myocardial infarction that occurred within 6 months; (4) supraventricular or ventricular arrhythmia requiring treatment or intervention.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
524 participants (estimated)

Study arms

  • Experimental
    HR070803+Oxaliplatin+5-FU/LV

    HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate

    Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate

  • Active comparator
    GX

    gemcitabine; capecitabine

    Drug: gemcitabine; capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Disease-free survival (DFS)

    Disease-free survival is defined as the time from date of randomization until the date of the first cancer-related event, second cancer, or death from any cause.

    Time frame: From study start until 338 DFS events have occurred (approximately 21 months after last patient enrollment)

Secondary outcomes

  1. Overall survival (OS)

    OS is defined as the time from date of randomization until the date of death from any cause.

    Time frame: From date of randomization until the date of death from any cause, assessed up to 37 months

  2. 3-year disease-free survival rate

    Disease-free survival within 3 years

    Time frame: up to 36 months following the date the first patient was randomized

  3. 5-year disease-free survival rate

    Disease-free survival within 5 years

    Time frame: up to 60 months following the date the first patient was randomized

  4. 3-year overall survival rate

    Overall survival within 3 years

    Time frame: up to 36 months following the date the first patient was randomized

  5. 5-year overall survival rate

    Overall survival within 5 years

    Time frame: up to 60 months following the date the first patient was randomized

07

Study locations

1 site
  • Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: Yes — study protocol and ICF, CSR will be shared.

Supporting information: Study protocol, Informed consent form, Clinical study report

Time frame: Ending of trials, preserved for 10 years.

Access criteria: Researchers within pancreatic cancer field.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2024; primary completion for Mar 2027, 37 months later.

Of 46 non-industry phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 79. This study's planned 37 months is below that.

Counting every sponsor, half of 84 studies reached it within 60 months; a quarter within 36 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Jan 22, 2024
StartEst.
Feb 5, 2024
Primary completionEst.
Mar 30, 2027
CompletionEst.
Jul 30, 2028
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06217042
Lead sponsor
Fudan University
Responsible party
Xian-Jun Yu (Professor, Fudan University) — Principal investigator
First posted
Jan 22, 2024
Start date
Feb 5, 2024 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Jan 22, 2024

Study contacts

Si Shi, PhD
Contact
shisi@fudanpci.org
+86 18917266285
Si Shi, PhD
principal investigator · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan Liposome HR070803 · Oxaliplatin · Fluorouracil · Leucovorin

Start the discussion